NAV

Marizomib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Marizomib
DrugBank Accession Number
DB11762
Background

Marizomib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Malignant Glioma, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 313.78
Monoisotopic: 313.1080858
Chemical Formula
C15H20ClNO4
Synonyms
  • Marizomib
External IDs
  • Npi 0052
  • NPI-0052

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Oxoprolines / 1,4-oxazepines / Pyrrolidine-2-ones / Beta propiolactones / Secondary carboxylic acid amides / Secondary alcohols / Oxetanes / Carboxylic acid esters / Lactams / Oxacyclic compounds
show 9 more
Substituents
2-pyrrolidone / Alcohol / Aliphatic heteropolycyclic compound / Alkyl chloride / Alkyl halide / Alpha-amino acid or derivatives / Azacycle / Beta_propiolactone / Carbonyl group / Carboxamide group
show 22 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
organochlorine compound, organic heterobicyclic compound, beta-lactone, gamma-lactam, salinosporamide (CHEBI:48045)
Affected organisms
Not Available

Chemical Identifiers

UNII
703P9YDP7F
CAS number
437742-34-2
InChI Key
NGWSFRIPKNWYAO-SHTIJGAHSA-N
InChI
InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1
IUPAC Name
(1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl](hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione
SMILES
C[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]1CCCC=C1

References

General References
Not Available
PubChem Compound
11347535
PubChem Substance
347828116
ChemSpider
9522473
BindingDB
50398608
ChEBI
48045
ChEMBL
CHEMBL371405
ZINC
ZINC000003990364
Wikipedia
Salinosporamide_A

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Active Not RecruitingTreatmentNewly diagnosed Glioblastoma Multiforme (GBM)1
2CompletedTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1
2TerminatedTreatmentAnaplastic Ependymoma / Ependymoma1
1Active Not RecruitingTreatmentDiffuse Glioma / Diffuse Intrinsic Pontine Gliomas (DIPG) / Pediatric Brain Tumor / Pediatric Brainstem Glioma / Pediatric Cancer / Recurrent Childhood Brainstem Glioma1
1CompletedOtherLymphoma / Melanoma / Multiple Myeloma (MM) / Non-Small Cell Lung Cancer (NSCLC) / Pancreatic Cancer1
1CompletedTreatmentAdvanced Malignant Neoplasm1
1CompletedTreatmentCancer / Lymphoma1
1CompletedTreatmentHigh Grade Glioma: Glioblastoma (GBM) / Malignant Glioma1
1CompletedTreatmentMultiple Myeloma (MM) / Refractory Multiple Myeloma / Relapsed Multiple Myeloma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.29 mg/mLALOGPS
logP1.39ALOGPS
logP1.24Chemaxon
logS-2.4ALOGPS
pKa (Strongest Acidic)10.32Chemaxon
pKa (Strongest Basic)-2.2Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area75.63 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity77.39 m3·mol-1Chemaxon
Polarizability31.62 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 20:46 / Updated at February 21, 2021 18:53